Oncolytics Biotech (ONCY) Current Assets (2009 - 2026)

Oncolytics Biotech (ONCY) has reported Current Assets for 18 consecutive years, with $7.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets fell 48.16% year-over-year to $7.1 million in Q2 2026; TTM through Jun 2026 was $7.1 million, a 48.16% decrease from a year earlier, with the FY2025 full-year figure at $6.8 million, down 44.97% from the prior year.
• Current Assets was $7.1 million for Q2 2026 at Oncolytics Biotech, up from $6.8 million in the prior quarter.
• Over five years, Current Assets peaked at $34.4 million in Q1 2022 and troughed at $6.8 million in Q4 2025.
• A 5-year average of $21.1 million and a median of $23.1 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets climbed 15.45% in 2023 and slumped 51.81% in 2024, its largest moves.
• Over 5 years, Current Assets stood at $26.3 million in 2022, then climbed by 6.66% to $28.0 million in 2023, then tumbled by 51.81% to $13.5 million in 2024, then tumbled by 49.35% to $6.8 million in 2025, then gained by 3.29% to $7.1 million in 2026.
• The last three Current Assets figures came in at $7.1 million (Q2 2026), $6.8 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.